Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

详细信息    查看全文

• 作者：Kelly-Anne Phillips ; Karin Ribi ; Zhuoxin Sun ; Alisa Stephens ; Alastair Thompson ; Vernon Harvey ; Beat Thü ; rlimann ; Fatima Cardoso ; Olivia Pagani ; Alan S. Coates ; Aron Goldhirsch ; Karen N. Price ; Ri
• 关键词：Cognitive function ; Breast cancer ; Aromatase inhibitor ; Tamoxifen ; Letrozole ; Quality of life
• 刊名：The Breast
• 出版年：2010
• 出版时间：October 2010
• 年：2010
• 卷：19
• 期：5
• 页码：388-395
• 全文大小：490 K

文摘

Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B + C; N = 65) vs. tamoxifen (A + D; N = 55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores = 0.28, P = 0.04, 95 % CI: 0.02, 0.54, Cohen’s D = 0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen.